UBS Group Reiterates "Neutral" Rating for Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International (NYSE:CRL - Get Free Report)'s stock had its "neutral" rating reaffirmed by equities researchers at UBS Group in a research report issued on Friday, MarketBeat.com reports. They currently have a $185.00 price target on the medical research company's stock, down from their previous price target of $250.00. UBS Group's price objective indicates a potential upside of 12.97% from the stock's previous close.

CRL has been the subject of a number of other reports. Bank of America lowered their price target on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. CLSA cut shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target for the company. in a research note on Monday, November 18th. TD Cowen increased their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research report on Monday, November 11th. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They issued a "sell" rating and a $151.00 price objective for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of Charles River Laboratories International in a research note on Tuesday. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $209.00.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL traded down $2.04 on Friday, reaching $163.77. The company's stock had a trading volume of 1,146,633 shares, compared to its average volume of 1,023,830. The company has a 50-day simple moving average of $191.67 and a 200 day simple moving average of $198.72. Charles River Laboratories International has a 52-week low of $160.85 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market cap of $8.37 billion, a P/E ratio of 20.50, a PEG ratio of 6.62 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same quarter last year, the business posted $2.72 earnings per share. The firm's revenue was down 1.6% on a year-over-year basis. As a group, equities research analysts anticipate that Charles River Laboratories International will post 10.18 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.30% of the company's stock.

Institutional Trading of Charles River Laboratories International

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in shares of Charles River Laboratories International in the 3rd quarter worth $601,000. JPMorgan Chase & Co. boosted its stake in Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after acquiring an additional 85,759 shares in the last quarter. State Street Corp boosted its stake in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock worth $9,064,000 after purchasing an additional 3,268 shares during the last quarter. Finally, Neo Ivy Capital Management acquired a new position in shares of Charles River Laboratories International during the third quarter worth $966,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).